• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

治疗抗菌药物管理中结果排序的可取性 (DOOR MAT):在存在药物耐药性的情况下评估抗生素选择策略的框架。

Desirability of Outcome Ranking for the Management of Antimicrobial Therapy (DOOR MAT): A Framework for Assessing Antibiotic Selection Strategies in the Presence of Drug Resistance.

机构信息

Research Service, Veterans Affairs Northeast Ohio Healthcare System, Cleveland, Ohio, USA.

Geriatric Research Education and Clinical Center, Veterans Affairs Northeast Ohio Healthcare System, Cleveland, Ohio, USA.

出版信息

Clin Infect Dis. 2021 Jul 15;73(2):344-350. doi: 10.1093/cid/ciaa1769.

DOI:10.1093/cid/ciaa1769
PMID:33245333
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8516503/
Abstract

The complexities of antibiotic resistance mean that successful stewardship must consider both the effectiveness of a given antibiotic and the spectrum of that therapy to minimize imposing further selective pressure. To meet this challenge, we propose the Desirability of Outcome Ranking approach for the Management of Antimicrobial Therapy (DOOR MAT), a flexible quantitative framework that evaluates the desirability of antibiotic selection. Herein, we describe the steps required to implement DOOR MAT and present examples to illustrate how the desirability of treatment selection can be evaluated using resistance information. While treatments and the scoring of treatment selections must be adapted to specific clinical settings, the principle of DOOR MAT remains constant: The most desirable antibiotic choice effectively treats the patient while exerting minimal pressure on future resistance.

摘要

抗生素耐药性的复杂性意味着成功的管理必须同时考虑给定抗生素的有效性和该治疗的广谱性,以最大限度地减少进一步施加的选择压力。为了应对这一挑战,我们提出了用于管理抗菌治疗的结果排序方法(Desirability of Outcome Ranking approach for the Management of Antimicrobial Therapy,DOOR MAT),这是一种灵活的定量框架,用于评估抗生素选择的适宜性。在此,我们描述了实施 DOOR MAT 所需的步骤,并提供了示例来说明如何使用耐药信息评估治疗选择的适宜性。虽然治疗方法和治疗选择的评分必须适应特定的临床环境,但 DOOR MAT 的原则保持不变:最理想的抗生素选择可以有效地治疗患者,同时对未来的耐药性施加最小的压力。

相似文献

1
Desirability of Outcome Ranking for the Management of Antimicrobial Therapy (DOOR MAT): A Framework for Assessing Antibiotic Selection Strategies in the Presence of Drug Resistance.治疗抗菌药物管理中结果排序的可取性 (DOOR MAT):在存在药物耐药性的情况下评估抗生素选择策略的框架。
Clin Infect Dis. 2021 Jul 15;73(2):344-350. doi: 10.1093/cid/ciaa1769.
2
Desirability of Outcome Ranking for the Management of Antimicrobial Therapy (DOOR MAT) Reveals Improvements in the Treatment of Bloodstream Infections Caused by Escherichia coli and Klebsiella pneumoniae in Patients from the Veterans Health Administration.期望结果排序在抗菌治疗管理中的应用(DOOR MAT),改善退伍军人医疗保健系统中由大肠杆菌和肺炎克雷伯菌引起的血流感染的治疗效果。
Clin Infect Dis. 2021 Oct 5;73(7):1231-1238. doi: 10.1093/cid/ciab384.
3
Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT).使用管理抗生素治疗的结果偏好排序方法(DOOR-MAT)比较快速诊断在治疗血流感染中的临床实用性。
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0044121. doi: 10.1128/AAC.00441-21.
4
The DOOR to Antibiotic Stewardship: Refining Assessments of Interventions With Desirability of Outcome Ranking.抗生素管理的 DOOR 途径:通过结果排序的可操作性评估来优化干预措施。
J Pharm Pract. 2022 Jun;35(3):403-406. doi: 10.1177/0897190020987130. Epub 2021 Jan 12.
5
Desirability of outcome ranking and quality life measurement for antimicrobial research in organ transplantation.器官移植中抗菌药物研究的结果排序和生活质量测量的可取性。
Transpl Infect Dis. 2022 Oct;24(5):e13888. doi: 10.1111/tid.13888.
6
Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR).结果排名的可取性(DOOR)和根据抗生素风险持续时间调整的反应(RADAR)。
Clin Infect Dis. 2015 Sep 1;61(5):800-6. doi: 10.1093/cid/civ495. Epub 2015 Jun 25.
7
Antimicrobial Stewardship Programs: Principles and Practice.抗菌药物管理计划:原则与实践。
Med Clin North Am. 2018 Sep;102(5):797-803. doi: 10.1016/j.mcna.2018.04.003. Epub 2018 Jun 15.
8
Desirability-based multi-criteria virtual screening of selective antimicrobial cyclic β-hairpin cationic peptidomimetics.基于期望的选择性抗菌环 β-发夹阳离子环肽类模拟物的多准则虚拟筛选。
Curr Pharm Des. 2013;19(12):2148-63. doi: 10.2174/1381612811319120003.
9
Day at the Races: Comparing BioFire FilmArray Blood Culture ID Panels With Verigene Blood Culture Panel in Gram-Negative Bloodstream Infections Using DOOR-MAT Analysis.赛马日:使用 DOOR-MAT 分析比较生物梅里埃 FilmArray 血培养 ID 检测板与 Verigene 血培养 panel 在革兰氏阴性菌血流感染中的应用。
Clin Infect Dis. 2021 Sep 15;73(6):1103-1106. doi: 10.1093/cid/ciab262.
10
Unlocking the DOOR-how to design, apply, analyse, and interpret desirability of outcome ranking endpoints in infectious diseases clinical trials.解锁 DOOR-如何在传染病临床试验中设计、应用、分析和解释结局排序偏好的方法。
Clin Microbiol Infect. 2023 Aug;29(8):1024-1030. doi: 10.1016/j.cmi.2023.05.003. Epub 2023 May 12.

引用本文的文献

1
Clinical Outcomes of Early Phenotype-Desirable Antimicrobial Therapy for Enterobacterales Bacteremia.肠杆菌属菌血症早期符合表型的抗菌治疗的临床结局
JAMA Netw Open. 2024 Dec 2;7(12):e2451633. doi: 10.1001/jamanetworkopen.2024.51633.
2
Simplified Spectrum Score (S) app for pathogen-agnostic antimicrobial drug spectrum ranking to assess for antimicrobial de-escalation events.简化谱评分(S)应用程序,用于针对病原体的抗菌药物谱排序,以评估抗菌药物降级事件。
Sci Rep. 2024 Apr 29;14(1):9776. doi: 10.1038/s41598-024-60041-6.
3
A Composite Endpoint for Treatment Benefit According to Patient Preference.根据患者偏好确定治疗益处的复合终点
Stat Biopharm Res. 2022;14(4):408-422. doi: 10.1080/19466315.2022.2085783. Epub 2022 Jul 19.
4
The Future Ain't What It Used to Be…Out With the Old…In With the Better: Antibacterial Resistance Leadership Group Innovations.未来已不再是过去的样子……旧的不去……新的更好:抗菌耐药性领导集团创新。
Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S321-S330. doi: 10.1093/cid/ciad538.
5
Under the Hood: The Scientific Leadership, Clinical Operations, Statistical and Data Management, and Laboratory Centers of the Antibacterial Resistance Leadership Group.掩人耳目:抗菌耐药性领导组的科学领导力、临床运营、统计和数据管理以及实验室中心。
Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S288-S294. doi: 10.1093/cid/ciad529.
6
A case-control study of infections caused by producing New Delhi metallo-beta-lactamase-1: Predictors and outcomes.产新德里金属β-内酰胺酶-1 所致感染的病例对照研究:预测因素和结局。
Front Cell Infect Microbiol. 2022 Jul 28;12:867347. doi: 10.3389/fcimb.2022.867347. eCollection 2022.
7
Desirability of outcome ranking and quality life measurement for antimicrobial research in organ transplantation.器官移植中抗菌药物研究的结果排序和生活质量测量的可取性。
Transpl Infect Dis. 2022 Oct;24(5):e13888. doi: 10.1111/tid.13888.
8
Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT).使用管理抗生素治疗的结果偏好排序方法(DOOR-MAT)比较快速诊断在治疗血流感染中的临床实用性。
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0044121. doi: 10.1128/AAC.00441-21.
9
Desirability of Outcome Ranking for the Management of Antimicrobial Therapy (DOOR MAT) Reveals Improvements in the Treatment of Bloodstream Infections Caused by Escherichia coli and Klebsiella pneumoniae in Patients from the Veterans Health Administration.期望结果排序在抗菌治疗管理中的应用(DOOR MAT),改善退伍军人医疗保健系统中由大肠杆菌和肺炎克雷伯菌引起的血流感染的治疗效果。
Clin Infect Dis. 2021 Oct 5;73(7):1231-1238. doi: 10.1093/cid/ciab384.
10
Day at the Races: Comparing BioFire FilmArray Blood Culture ID Panels With Verigene Blood Culture Panel in Gram-Negative Bloodstream Infections Using DOOR-MAT Analysis.赛马日:使用 DOOR-MAT 分析比较生物梅里埃 FilmArray 血培养 ID 检测板与 Verigene 血培养 panel 在革兰氏阴性菌血流感染中的应用。
Clin Infect Dis. 2021 Sep 15;73(6):1103-1106. doi: 10.1093/cid/ciab262.

本文引用的文献

1
Current evidence for therapy of ceftriaxone-resistant Gram-negative bacteremia.目前针对头孢曲松耐药的革兰氏阴性菌血症的治疗证据。
Curr Opin Infect Dis. 2020 Feb;33(1):78-85. doi: 10.1097/QCO.0000000000000623.
2
Average Weighted Accuracy: Pragmatic Analysis for a Rapid Diagnostics in Categorizing Acute Lung Infections (RADICAL) Study.平均加权准确率:快速诊断急性肺部感染(RADICAL)研究中的实用分析。
Clin Infect Dis. 2020 Jun 10;70(12):2736-2742. doi: 10.1093/cid/ciz437.
3
Antibiotics for Ceftriaxone-Resistant Gram-Negative Bacterial Bloodstream Infections.用于治疗对头孢曲松耐药的革兰氏阴性菌血流感染的抗生素
JAMA. 2019 Feb 12;321(6):613. doi: 10.1001/jama.2018.19349.
4
Appropriateness of antibiotic prescribing in the Emergency Department.急诊科抗生素使用的适宜性。
J Antimicrob Chemother. 2019 Feb 1;74(2):515-520. doi: 10.1093/jac/dky447.
5
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.哌拉西林-他唑巴坦与美罗培南对产 ESBLs 的大肠埃希菌或肺炎克雷伯菌血流感染且对头孢曲松耐药患者 30 天死亡率的影响:一项随机临床试验。
JAMA. 2018 Sep 11;320(10):984-994. doi: 10.1001/jama.2018.12163.
6
Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17).美国医疗中心 ICU 住院肺炎患者分离的革兰氏阴性菌的频率和抗菌药物敏感性(2015-17 年)。
J Antimicrob Chemother. 2018 Nov 1;73(11):3053-3059. doi: 10.1093/jac/dky279.
7
Association of Broad- vs Narrow-Spectrum Antibiotics With Treatment Failure, Adverse Events, and Quality of Life in Children With Acute Respiratory Tract Infections.广谱与窄谱抗生素与急性呼吸道感染儿童治疗失败、不良事件及生活质量的关联
JAMA. 2017 Dec 19;318(23):2325-2336. doi: 10.1001/jama.2017.18715.
8
Antimicrobial Nonsusceptibility of Gram-Negative Bloodstream Isolates, Veterans Health Administration System, United States, 2003-2013.美国退伍军人健康管理系统2003 - 2013年革兰氏阴性血流分离株的抗菌药物不敏感性
Emerg Infect Dis. 2017 Nov;23(11):1815-1825. doi: 10.3201/eid2311.161214.
9
Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by and .美国以 和 为主的耐碳青霉烯类革兰氏阴性菌感染的患病率。
Open Forum Infect Dis. 2017 Aug 16;4(3):ofx176. doi: 10.1093/ofid/ofx176. eCollection 2017 Summer.
10
Incidence of Extended-Spectrum β-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella Infections in the United States: A Systematic Literature Review.美国产超广谱β-内酰胺酶(ESBL)的大肠杆菌和克雷伯菌感染的发生率:系统文献回顾。
Infect Control Hosp Epidemiol. 2017 Oct;38(10):1209-1215. doi: 10.1017/ice.2017.156. Epub 2017 Jul 31.